Last reviewed · How we verify

Dapagliflozin/Pioglitazone — Competitive Intelligence Brief

Dapagliflozin/Pioglitazone (Dapagliflozin/Pioglitazone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor / Thiazolidinedione combination. Area: Diabetes.

marketed SGLT2 inhibitor / Thiazolidinedione combination SGLT2 / PPAR-γ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin/Pioglitazone (Dapagliflozin/Pioglitazone) — Boryung Pharmaceutical Co., Ltd. This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dapagliflozin/Pioglitazone TARGET Dapagliflozin/Pioglitazone Boryung Pharmaceutical Co., Ltd marketed SGLT2 inhibitor / Thiazolidinedione combination SGLT2 / PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor / Thiazolidinedione combination class)

  1. Boryung Pharmaceutical Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin/Pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-pioglitazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: